IO Biotech

Contributing Author

Recent Articles by IO Biotech

Nov-12	IO Biotech Announces Participation in Upcoming Investor Conferences IOBT -6.00% GlobeNewswire
Nov-07	IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) IOBT GlobeNewswire
Oct-20	IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 IOBT GlobeNewswire
Sep-29	IO Biotech Provides Update Following Pre-BLA Meeting with FDA IOBT GlobeNewswire
Sep-23	IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025 IOBT GlobeNewswire
Sep-04	IO Biotech Announces Participation in Upcoming Investor Conferences IOBT GlobeNewswire
Aug-14	IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights IOBT GlobeNewswire
Aug-11	IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio plus KEYTRUDA (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed IOBT GlobeNewswire
Aug-10	IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma IOBT GlobeNewswire
May-20	IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference IOBT GlobeNewswire
May-14	IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights IOBT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.